Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Part 4: Clinical decision making - Interpretation of next generation sequencing results
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity
Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care
Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer
EAU 2026: Updates in NMIBC
Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC
Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer